| Cash Flow | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|
| Net loss | -23,502 | -27,232 | -69,995 |
| Stock-based compensation | 3,516 | 5,259 | 1,440 |
| Research and development expenses paid with convertible and promissory notes | - | - | 0 |
| Non-cash research and development services | 632 | 621 | 1,999 |
| Net accretion of discount/premium on debt securities | -2 | 73 | 556 |
| Accrued interest earned | - | - | 647 |
| Other | -56 | -6 | -43 |
| Prepaid expenses and other current assets | -1,420 | -4,360 | 8,235 |
| Interest receivable on marketable securities | 1,281 | 1,499 | - |
| Accounts payable | 4,849 | -1,055 | -122 |
| Accrued expenses | -211 | -1,373 | 4,510 |
| Other non-current assets | 80 | 174 | - |
| Other current liabilities and lease liabilities | 109 | -8 | -39 |
| Net cash used in operating activities | -14,490 | -21,168 | -71,602 |
| Purchase of property, plant and equipment | 21 | 0 | 24 |
| Purchases of marketable securities | 305,577 | 122,988 | 143,852 |
| Maturities of marketable securities | 28,311 | 21,689 | 25,018 |
| Net cash used in investing activities | -277,287 | -101,299 | -118,858 |
| Issuance of convertible notes | - | - | 0 |
| Issuance of preferred stock-Series BPreferred Stock | - | - | 8,433 |
| Issuance of series b preferred stock, net of issuance costs paid | 0 | 0 | - |
| Issuance of preferred stock-Series CPreferred Stock | - | - | 151,000 |
| Initial public offering, net of issuance costs paid | 0 | 269,102 | - |
| Payment of promissory note | - | - | 0 |
| Public offering, net of issuance costs | 414,335 | - | - |
| Preferred stock issuance costs | - | - | 447 |
| Pre-funded warrants, net of issuance costs | 28,120 | - | - |
| Exercise of stock options | 243 | 11 | 156 |
| Net cash provided by financing activities | 442,698 | 269,113 | 159,142 |
| Net increase (decrease) in cash and cash equivalents | 150,921 | 146,646 | -31,318 |
| Cash and cash equivalentsbeginning of period | 168,412 | 21,766 | 53,084 |
| Cash and cash equivalentsend of period | 319,333 | 168,412 | 21,766 |
Veradermics, Inc (MANE)
Veradermics, Inc (MANE)